← Back to Search

Hyperpolarized Xenon MRI for Lung Function Assessment in Healthy Subjects

N/A
Recruiting
Led By Grace E Parraga, PhD
Research Sponsored by Western University, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to perform a breath hold for up to 16 sec
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is testing if a new MRI technique can help assess lung function.

Who is the study for?
This trial is for healthy adults aged 18-85 who can hold their breath up to 16 seconds, have a BMI of 18-40, and a minimal smoking history. They must be in stable health and able to perform certain lung function tests. People with mental incapacitation, severe claustrophobia, implanted devices or metal in their body that cannot be removed are excluded.Check my eligibility
What is being tested?
The study is testing the use of hyperpolarized Xenon MRI technology on healthy subjects. It aims to develop tools for assessing image quality and consistency across repeated scans while also evaluating participants' lung function.See study design
What are the potential side effects?
Since this trial involves imaging technology rather than medication, side effects are minimal but may include discomfort from holding one's breath during the scan or feelings of claustrophobia inside the MRI machine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can hold my breath for up to 16 seconds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ventilation Defect Percent (VDP)
Secondary outcome measures
Apparent Diffusion Coefficients (ADC)
Dissolved Phase Spectroscopy Measurements

Side effects data

From 2020 Phase 3 trial • 38 Patients • NCT03417687
7%
Pruritus
7%
Hematemesis
7%
Hypoaesthesia oral
7%
Hair disorder
7%
Erythema
7%
Intestinal pseudo-obstruction
7%
Lacrimation increased
7%
Colitis
7%
Nausea
7%
Eye pruritus
7%
Restlessness
7%
Skin discolouration
100%
80%
60%
40%
20%
0%
Study treatment Arm
129Xe Before 133Xe
133Xe Before 129Xe

Trial Design

1Treatment groups
Experimental Treatment
Group I: Healthy VolunteersExperimental Treatment1 Intervention
Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.

Find a Location

Who is running the clinical trial?

London Health Sciences CentreOTHER
142 Previous Clinical Trials
49,868 Total Patients Enrolled
Western University, CanadaLead Sponsor
239 Previous Clinical Trials
57,433 Total Patients Enrolled
Grace E Parraga, PhDPrincipal InvestigatorRobarts Research Institute, The University of Western Ontario
14 Previous Clinical Trials
1,314 Total Patients Enrolled

Media Library

Healthy Volunteers Clinical Trial Eligibility Overview. Trial Name: NCT02484885 — N/A
Healthy Subjects Research Study Groups: Healthy Volunteers
Healthy Subjects Clinical Trial 2023: Healthy Volunteers Highlights & Side Effects. Trial Name: NCT02484885 — N/A
Healthy Volunteers 2023 Treatment Timeline for Medical Study. Trial Name: NCT02484885 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Aug 2025